Funding for this research was provided by:
National Health and Medical Research Council (1136130, 1141131, 1181053)
The University of Queensland ECR grant (UQECR1834805)
The University of Queensland
Accepted: 21 February 2022
First Online: 14 May 2022
: HWT, JPL, and KAA declare no conflict of interest. KS is a co-inventor on patent applications for NLRP3 inhibitors which have been licensed to Inflazome Ltd, a company headquartered in Dublin, Ireland. Inflazome is developing drugs that target the NLRP3 inflammasome to address unmet clinical needs in inflammatory disease. K.S. served on the Scientific Advisory Board of Inflazome in 2016–2017, and serves as a consultant to Quench Bio, USA and Novartis, Switzerland.
: All reported studies/experiments with human or animal subjects performed by the authors complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional/national research committee standards, and international/national/institutional guidelines).